{"title":"在治疗 Chittodvega（广泛性焦虑症）方面，评估青蒿（Jyotishmati）胶囊与舍曲林胶囊的疗效对比：随机对照试验方案。","authors":"Reeya Gamne, Sadhana Misar, Mayank Rai","doi":"10.12688/f1000research.139473.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Generalized anxiety disorder (GAD) <i>(Chittodvega)</i> is one among many types of mental disorders explained in Ayurveda. It can be defined as a <i>Chitta</i> (mind) + <i>Udvega</i> (anxiety)= <i>Chittodvega</i>- Anxious status of a mind. <i>Celastrus paniculatus</i> also known as <i>Jyotishmati</i> stimulates and improves the digestive fire and metabolism at a cellular level ( <i>Jatharagni and Majja dhatwagni).</i> It can be correlated to GAD. GAD is characterized by feelings of threat, restlessness, irritability, sleep disturbance, and tension, and symptoms such as palpitations, dry mouth, and sweating. It affects women more frequently than men and prevalence rates are high in midlife (prevalence in females over age 35: 10%) and older subjects. In modern medicine the first-line psychological and pharmaceutical treatments are selective serotonin reuptake inhibitors (SSRIs) like sertraline (SNRIs).</p><p><strong>Aim and objectives: </strong>To evaluate the comparative efficacy of <i>Jyotishmati</i> versus sertraline in the management of <i>Chittodvega.</i></p><p><strong>Methods: </strong>In this randomized active controlled double blind equivalence trial a total of 70 patients will be enrolled and divided into two equal groups. Patients between 20-50 years age of either gender having symptoms of <i>Chittodvega</i> and a Hamilton anxiety rating (HAM-A) scale score less than 24 (i.e., mild to moderate) will be selected for the study. In Group A, sertraline capsules 25 mg for first 7 days and then dose increased to 50 mg at bedtime for next 53 days and in Group B <i>Jyotishmati</i> Capsules 500 mg will be given twice a day after food with water for 60 days.</p><p><strong>Result and observation: </strong>The patients will be assessed on the HAM-A scale, serum cortisol and WHO Quality of Life on day 0, 30, 60 and 90 and data will be analyzed using paired and unpaired t-tests for continuous variables and chi-square tests for categorical variables to evaluate whether treatments are equivalent.</p><p><strong>Trial registration: </strong>CTRI No. REF/2023/07/069880 Date - 15/09/2023.</p>","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305454/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of comparative efficacy of <i>Celastrus paniculatus (Jyotishmati)</i> capsule versus sertraline capsule in the management of <i>Chittodvega</i> (generalized anxiety disorder): protocol for a randomized controlled trial.\",\"authors\":\"Reeya Gamne, Sadhana Misar, Mayank Rai\",\"doi\":\"10.12688/f1000research.139473.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Generalized anxiety disorder (GAD) <i>(Chittodvega)</i> is one among many types of mental disorders explained in Ayurveda. It can be defined as a <i>Chitta</i> (mind) + <i>Udvega</i> (anxiety)= <i>Chittodvega</i>- Anxious status of a mind. <i>Celastrus paniculatus</i> also known as <i>Jyotishmati</i> stimulates and improves the digestive fire and metabolism at a cellular level ( <i>Jatharagni and Majja dhatwagni).</i> It can be correlated to GAD. GAD is characterized by feelings of threat, restlessness, irritability, sleep disturbance, and tension, and symptoms such as palpitations, dry mouth, and sweating. It affects women more frequently than men and prevalence rates are high in midlife (prevalence in females over age 35: 10%) and older subjects. In modern medicine the first-line psychological and pharmaceutical treatments are selective serotonin reuptake inhibitors (SSRIs) like sertraline (SNRIs).</p><p><strong>Aim and objectives: </strong>To evaluate the comparative efficacy of <i>Jyotishmati</i> versus sertraline in the management of <i>Chittodvega.</i></p><p><strong>Methods: </strong>In this randomized active controlled double blind equivalence trial a total of 70 patients will be enrolled and divided into two equal groups. Patients between 20-50 years age of either gender having symptoms of <i>Chittodvega</i> and a Hamilton anxiety rating (HAM-A) scale score less than 24 (i.e., mild to moderate) will be selected for the study. In Group A, sertraline capsules 25 mg for first 7 days and then dose increased to 50 mg at bedtime for next 53 days and in Group B <i>Jyotishmati</i> Capsules 500 mg will be given twice a day after food with water for 60 days.</p><p><strong>Result and observation: </strong>The patients will be assessed on the HAM-A scale, serum cortisol and WHO Quality of Life on day 0, 30, 60 and 90 and data will be analyzed using paired and unpaired t-tests for continuous variables and chi-square tests for categorical variables to evaluate whether treatments are equivalent.</p><p><strong>Trial registration: </strong>CTRI No. REF/2023/07/069880 Date - 15/09/2023.</p>\",\"PeriodicalId\":12260,\"journal\":{\"name\":\"F1000Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305454/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"F1000Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/f1000research.139473.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.139473.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Evaluation of comparative efficacy of Celastrus paniculatus (Jyotishmati) capsule versus sertraline capsule in the management of Chittodvega (generalized anxiety disorder): protocol for a randomized controlled trial.
Background: Generalized anxiety disorder (GAD) (Chittodvega) is one among many types of mental disorders explained in Ayurveda. It can be defined as a Chitta (mind) + Udvega (anxiety)= Chittodvega- Anxious status of a mind. Celastrus paniculatus also known as Jyotishmati stimulates and improves the digestive fire and metabolism at a cellular level ( Jatharagni and Majja dhatwagni). It can be correlated to GAD. GAD is characterized by feelings of threat, restlessness, irritability, sleep disturbance, and tension, and symptoms such as palpitations, dry mouth, and sweating. It affects women more frequently than men and prevalence rates are high in midlife (prevalence in females over age 35: 10%) and older subjects. In modern medicine the first-line psychological and pharmaceutical treatments are selective serotonin reuptake inhibitors (SSRIs) like sertraline (SNRIs).
Aim and objectives: To evaluate the comparative efficacy of Jyotishmati versus sertraline in the management of Chittodvega.
Methods: In this randomized active controlled double blind equivalence trial a total of 70 patients will be enrolled and divided into two equal groups. Patients between 20-50 years age of either gender having symptoms of Chittodvega and a Hamilton anxiety rating (HAM-A) scale score less than 24 (i.e., mild to moderate) will be selected for the study. In Group A, sertraline capsules 25 mg for first 7 days and then dose increased to 50 mg at bedtime for next 53 days and in Group B Jyotishmati Capsules 500 mg will be given twice a day after food with water for 60 days.
Result and observation: The patients will be assessed on the HAM-A scale, serum cortisol and WHO Quality of Life on day 0, 30, 60 and 90 and data will be analyzed using paired and unpaired t-tests for continuous variables and chi-square tests for categorical variables to evaluate whether treatments are equivalent.
Trial registration: CTRI No. REF/2023/07/069880 Date - 15/09/2023.
F1000ResearchPharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.00
自引率
0.00%
发文量
1646
审稿时长
1 weeks
期刊介绍：
F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
